Coronary Artery Calcium Scoring (CAC)

Coronary Artery Calcium Scoring uses a low-dose, noncontrast cardiac CT scan to measure calcified coronary plaque, helping clinicians reclassify cardiovascular risk when ordinary risk estimates leave a treatment decision uncertain.

Also known as: CAC scan, calcium score, Agatston score, coronary calcium test, heart scan

Context

Atherosclerotic cardiovascular disease is usually managed from risk estimates, not from direct proof of plaque. Age, sex, blood pressure, smoking, diabetes, cholesterol, kidney disease, family history, ApoB Screening, and Lp(a) Screening all shape the map. None of them shows whether calcified plaque is already present in the coronary arteries.

Coronary artery calcium scoring fills that narrow gap. The test is a noncontrast cardiac CT scan that detects calcium deposits in coronary plaque and reports an Agatston score. The result is not a full coronary anatomy study. It doesn’t show soft plaque well, doesn’t grade stenosis the way Coronary CT Angiography can, and doesn’t diagnose chest pain. It answers one focused question: how much calcified coronary atherosclerosis is visible now?

That narrowness is the point. A score of zero can lower near-term risk estimates in the right person. A clearly positive score makes an abstract risk calculation concrete. A score of 100 or higher, or one above the 75th percentile for age and sex, can shift a clinician-patient discussion toward more intensive prevention. The scan is most useful when the decision is already on the table.

Problem

The recurring problem is cardiovascular-risk uncertainty. A reader may have borderline or intermediate estimated risk, mild LDL-C elevation, discordant apoB, high Lp(a), family history, or strong reluctance to start medication. The lab map points in one direction, but not clearly enough to settle the plan.

The opposite problem is false certainty. A person can read a normal lipid panel as proof of clean arteries, or read a high LDL-C value as if it already shows plaque. Both moves confuse risk factors with measured disease.

CAC helps only when the uncertainty is specific. If the person has symptoms, known coronary disease, prior myocardial infarction, prior stent, prior bypass surgery, or a very high-risk clinical condition, the question usually isn’t “should we refine risk?” It is “what clinical evaluation or treatment is needed?” CAC is a risk-stratification tool for selected asymptomatic adults, not a universal screen.

Forces

• Cardiovascular risk calculators are useful, but individual risk remains uncertain near treatment thresholds.
• CAC directly measures calcified plaque burden, but it misses non-calcified plaque and can understate risk in younger adults.
• A zero score can reassure the right person, but it isn’t a lifetime warranty.
• A positive score can motivate prevention, but it can also trigger Single-Biomarker Tunnel Vision.
• The scan is inexpensive and accessible, yet repeat testing adds radiation, cost, and anxiety if no decision will change.
• Guidelines support selective use, while the USPSTF still finds outcome evidence insufficient for routine addition to traditional risk assessment in asymptomatic adults.

Solution

Use CAC as a one-question decision aid when cardiovascular prevention is uncertain after ordinary risk assessment. The scan should be ordered, interpreted, and acted on by a qualified clinician who can place the result beside symptoms, family history, blood pressure, diabetes status, smoking, kidney disease, LDL-C, non-HDL-C, apoB, Lp(a), medications, and the person’s risk tolerance.

The 2026 ACC/AHA dyslipidemia guidance supports selective noncontrast CAC scanning for men older than 40 and women older than 45 with borderline or intermediate 10-year risk. The older 2018 cholesterol guideline used a similar decision frame for adults 40 to 75 without diabetes when the statin decision remained uncertain after risk discussion. The specific age bands and risk calculators change over time, but the use case is stable: CAC is for uncertain primary-prevention decisions, not for curiosity.

Read the score as a category, not as a personality trait:

Repeat timing should have a reason. A clinician may repeat CAC after several years when a zero score is being used to defer treatment and the person’s risk has changed. Repeating the scan every few months is almost never the useful move. Plaque biology, radiation exposure, measurement variability, and decision timing all argue for restraint.

Evidence

Evidence tier: Practitioner consensus for the selective screening pattern; Observational (human, large) for CAC as a risk marker. Cohort evidence for risk prediction is strong, and selective use enjoys broad cardiology support. The evidence is thinner for a blanket strategy of adding CAC to every asymptomatic adult’s risk assessment and proving fewer events.

The MESA evidence is the backbone. In a multi-ethnic cohort of 6,814 adults aged 45 to 84 without clinical cardiovascular disease at baseline, 10-year ASCVD event rates rose in a graded pattern across CAC categories. CAC zero identified a large group with low near-term event rates, while higher scores identified progressively higher risk (Budoff et al., 2018).

Risk-prediction work supports the same use. McClelland and colleagues developed a 10-year coronary heart disease risk prediction model using CAC and traditional risk factors in MESA, then validated it in the Heinz Nixdorf Recall and Dallas Heart Study cohorts. CAC improved risk classification beyond traditional factors, which is exactly why clinicians use it near treatment thresholds (McClelland et al., 2015).

The practical review literature is favorable but still selective. Greenland, Blaha, Budoff, Erbel, and Watson called CAC a highly specific feature of coronary atherosclerosis and described it as a reproducible tool for planning primary prevention in asymptomatic people. The National Lipid Association scientific statement later provided practice recommendations across primary-prevention groups, including borderline and intermediate risk, diabetes or metabolic syndrome, and severe hypercholesterolemia (Greenland et al., 2018; Orringer et al., 2021).

Guidelines have moved CAC further into mainstream lipid prevention. The 2018 AHA/ACC cholesterol guideline used CAC to refine uncertain statin decisions. A CAC of zero often supported deferral, except in smokers, diabetes, and strong premature family history. A score of 1 to 99 favored statin therapy, especially after age 55. A score of 100 or higher, or at or above the 75th percentile, generally supported statin therapy unless the clinician-patient discussion said otherwise. The 2026 ACC/AHA dyslipidemia update expanded CAC use as part of risk reclassification.

The counterweight matters. The USPSTF acknowledges that CAC can improve calibration, discrimination, and reclassification when added to traditional risk models, but holds the evidence insufficient to know whether CAC-guided treatment decisions reduce cardiovascular events or mortality in asymptomatic adults. That is not a claim that CAC is useless. It is a claim about a missing outcomes trial for the screening strategy.

How It Plays Out

A 48-year-old man has borderline estimated risk, LDL-C that is not alarming, apoB that is higher than expected, and a father who had a myocardial infarction at 54. CAC can clarify whether visible calcified plaque is already present. A zero score may support a more measured plan. A score above 100 changes the conversation.

A 61-year-old woman has high Lp(a), well-controlled blood pressure, good fitness, and no symptoms. CAC does not measure Lp(a), but it can show how much near-term plaque burden is already visible and help a clinician decide whether the inherited risk signal should shift lipid-management intensity or follow-up timing.

A 39-year-old with chest pain should not use CAC as a shortcut. The scan may miss non-calcified plaque, and the clinical question is symptomatic evaluation. That belongs with a clinician who can decide whether ECG, labs, stress testing, CCTA, emergency evaluation, or another pathway is appropriate.

A 55-year-old gets a CAC score of zero and interprets it as permission to ignore apoB, alcohol intake, sleep apnea symptoms, and rising blood pressure. That is Single-Biomarker Tunnel Vision. CAC zero lowers one part of the risk estimate. It doesn’t convert the rest of the map into noise.

Consequences

Benefits. CAC makes an invisible process concrete. A positive score turns abstract risk factors into visible plaque burden and helps a clinician explain why prevention matters. A zero score can prevent overtreatment in selected people whose calculated risk is higher than their measured calcified plaque burden suggests.

CAC also sharpens the sequencing of preventive tests. Comprehensive Annual Bloodwork supplies the lipid and metabolic context. ApoB estimates particle burden. Lp(a) identifies inherited particle risk. CAC asks whether calcified coronary plaque is already visible. Those are different questions, and the differences matter.

Liabilities. CAC can miss the plaque a reader most wants to know about. Non-calcified plaque can exist with CAC zero, especially in younger adults and in some higher-risk clinical contexts. That is the reason CAC should not be used to evaluate symptoms or to override a clinician’s concern.

The scan can also start a cascade. An unexpected positive result can lead to repeat imaging, anxiety, medication conflict, or downstream tests that were not part of the original decision rule. A very high score deserves clinical interpretation, but repeating the scan to watch the number is Biomarker Treadmill in slow motion.

Radiation and cost are small but real. The American Heart Association describes the radiation exposure as similar to a mammogram and notes that insurance coverage is inconsistent, with typical out-of-pocket cost around $100 to $400. That is cheap compared with many longevity tests. It is still not zero-risk or zero-cost medicine.

Related Articles

Sources

• American College of Cardiology. “ACC, AHA Release New Clinical Guideline For Managing Dyslipidemia.” March 13, 2026. https://www.acc.org/latest-in-cardiology/journal-scans/2026/03/13/15/20/acc-aha-release-new-clinical-guideline-for-managing-dyslipidemia
• American Heart Association. “2026 Guideline on the Management of Dyslipidemia.” Professional Heart Daily. 2026. https://professional.heart.org/en/science-news/2026-guideline-on-the-management-of-dyslipidemia
• American Heart Association. “Coronary Artery Calcium Test.” Last reviewed February 21, 2025. https://www.heart.org/en/health-topics/heart-attack/diagnosing-a-heart-attack/cac-test
• Budoff, Matthew J., Rebekah Young, Gregory Burke, J. Jeffrey Carr, Robert C. Detrano, Aaron R. Folsom, Richard Kronmal, et al. “Ten-Year Association of Coronary Artery Calcium With Atherosclerotic Cardiovascular Disease Events: The Multi-Ethnic Study of Atherosclerosis.” European Heart Journal 39, no. 25 (2018): 2401-2408. https://doi.org/10.1093/eurheartj/ehy217
• Greenland, Philip, Michael J. Blaha, Matthew J. Budoff, Raimund Erbel, and Karol E. Watson. “Coronary Calcium Score and Cardiovascular Risk.” Journal of the American College of Cardiology 72, no. 4 (2018): 434-447. https://doi.org/10.1016/j.jacc.2018.05.027
• Grundy, Scott M., Neil J. Stone, Alison L. Bailey, Craig Beam, Kim K. Birtcher, Roger S. Blumenthal, Lynne T. Braun, et al. “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.” Circulation 139, no. 25 (2019): e1082-e1143. https://doi.org/10.1161/CIR.0000000000000625
• McClelland, Robyn L., Nathan W. Jorgensen, Matthew Budoff, Michael J. Blaha, Wendy S. Post, Richard A. Kronmal, Diane E. Bild, et al. “10-Year Coronary Heart Disease Risk Prediction Using Coronary Artery Calcium and Traditional Risk Factors: Derivation in the MESA With Validation in the HNR and DHS.” Journal of the American College of Cardiology 66, no. 15 (2015): 1643-1653. https://doi.org/10.1016/j.jacc.2015.08.035
• Orringer, Carl E., Michael J. Blaha, Ron Blankstein, Matthew J. Budoff, Ronald B. Goldberg, Edward A. Gill, Kevin C. Maki, Laxmi Mehta, and Terry A. Jacobson. “The National Lipid Association Scientific Statement on Coronary Artery Calcium Scoring to Guide Preventive Strategies for ASCVD Risk Reduction.” Journal of Clinical Lipidology 15, no. 1 (2021): 33-60. https://doi.org/10.1016/j.jacl.2020.12.005
• U.S. Preventive Services Task Force. “Cardiovascular Disease: Risk Assessment With Nontraditional Risk Factors.” Final Recommendation Statement. July 10, 2018. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/cardiovascular-disease-screening-using-nontraditional-risk-assessment

Medical and Legal Boundary

This entry is a reference, not medical advice. It describes published evidence, regulatory status, and common clinical practice patterns. It does not diagnose, prescribe, or replace a clinician’s judgment for a specific person.

CAC scanning should be considered and interpreted by a qualified clinician in the context of age, sex, symptoms, pregnancy status, medical history, family history, blood pressure, smoking, diabetes, kidney disease, inflammatory disease, medications, LDL-C, non-HDL-C, apoB, Lp(a), prior imaging, and personal risk tolerance. Chest pain, shortness of breath, exertional symptoms, known coronary disease, prior myocardial infarction, prior stent, prior bypass surgery, and very high-risk clinical states require clinician-directed evaluation rather than self-directed calcium scoring.